Nanobiotix (NASDAQ:NBTX) requested a temporary halt of trading in its ordinary shares on Euronext Paris starting May 21, 2026, at 9:00 a.m. CEST.
The halt supports allocation confirmations and pricing for a previously announced Global Offering of ADSs, ordinary shares, and pre-funded warrants, with trading expected to resume around 3:30 p.m. Paris time.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – NBTX
-6.90%
13 alerts
-6.90%Session close to close
+4.6%Peak Tracked
-5.1%Trough Tracked
$2.09BMarket Cap
0.7xRel. Volume
In the May 21 session, NBTX declined 6.90%, reflecting a notable negative market reaction.
Argus tracked a peak move of +4.6% during that session.
Argus tracked a trough of -5.1% from its starting point during tracking.
Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
The stock moved -6.9% in the session following this news. A negative reaction despite prior positive...
Analysis
The stock moved -6.9% in the session following this news. A negative reaction despite prior positive clinical updates fits a history where financing and data events have produced volatile swings, including declines of 5.56% and 3.92% after favorable announcements. The trading halt and Global Offering may have sharpened focus on dilution and capital needs. Such moves can reflect re-pricing of risk as new shares and warrants are placed, especially after a large run from the 52-week low.
Key Figures
Trading halt date:May 21, 2026Trading resume time Paris:3:30 p.m.Trading resume time New York:9:30 a.m.+2 more
5 metrics
Trading halt dateMay 21, 2026Effective from Euronext Paris market opening
Trading resume time Paris3:30 p.m.Expected Euronext Paris resumption on May 21, 2026
Trading resume time New York9:30 a.m.Expected U.S. market resume time for Euronext Paris trading
Nominal value per share€0.03Ordinary Share nominal value referenced in Global Offering
EU regulation referenceRegulation (EU) 2017/1129 Article 2(e)Defines qualified investors for International Offering
Report of €32.6M revenue, narrowed net loss and cash runway into early 2028.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Stock has shown mixed reactions, with sizable moves on clinical and financing-related updates and occasional selloffs on otherwise positive data.
Recent Company History
Over recent months, Nanobiotix has combined clinical progress with capital and disclosure actions. Positive full‑year 2025 results and business updates on Mar 31 coincided with a 10.37% gain, while protocol changes to the Phase 3 NANORAY‑312 trial on May 4 saw an 11.59% rise. Conversely, encouraging preclinical and early clinical data on Apr 20 and May 17 were followed by declines. The current trading halt and Global Offering follow this pattern of material financing and clinical catalysts.
Key Terms
american depositary shares, pre-funded warrants, qualified investors, regulation (eu) 2017/1129, +2 more
6 terms
american depositary sharesfinancial
"a public offering of its American Depositary Shares (“ADSs”), each ADS representing"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
pre-funded warrantsfinancial
"an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
qualified investorsregulatory
"exclusively addressed to “qualified investors” in Europe (including France) within"
Qualified investors are individuals or institutions that meet regulatory standards—such as a minimum income, net worth, or professional expertise—allowing them access to investment opportunities not open to the general public. Think of them as a financial "VIP" group: they can buy private deals, complex products, or early-stage securities that may offer higher returns but also carry greater risk and less public information, so their status matters because it changes what investments are available and what protections apply.
regulation (eu) 2017/1129regulatory
"within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended"
An EU law that sets uniform rules for the detailed disclosure document companies must give when offering securities to the public or listing them on markets. It matters to investors because it forces issuers to present a clear, standardized “label” of information—risks, business model, finances and terms—so you can compare offerings and spot missing or misleading claims. Think of it as a required ingredient list and instructions for financial products sold across the EU.
global offeringfinancial
"the “International Offering” and, together with the U.S. Offering, the “Global Offering”"
A global offering is when a company sells its shares or other securities to investors in multiple countries at the same time, combining new shares and sometimes existing ones. It matters to investors because it can change how many shares are available, affect the stock’s price and liquidity, and bring in capital or let insiders cash out—much like a concert releasing tickets worldwide at once, expanding the buyer pool and influencing demand and resale value.
trading halttechnical
"trading of its ordinary shares on the regulated market of Euronext Paris ... will be temporarily halted"
A trading halt is a temporary pause on buying and selling a particular stock imposed by an exchange or regulator, like pressing the pause button on a game so everyone can catch up. It is used to give the market time to absorb important new information or to prevent chaotic price swings, and matters to investors because it freezes the ability to trade, delays price discovery, and can change risk and strategy until normal trading resumes.
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company’s request, from the opening of the market at 9:00 a.m. CEST. This trading halt takes place in the context of the previously announced offering consisting of (i) a public offering of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and certain other countries (excluding the United States and Canada) (the “International Offering” and, together with the U.S. Offering, the “Global Offering”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Global Offering.
This suspension will be effective until a new communication is released by the Company. Trading on Euronext Paris is expected to resume on May 21, 2026, at approximately at approximately 3:30 p.m. (Paris time) / 9:30 a.m. (New York time).
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States), amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
Contacts
Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com
Global – uncapped Communications Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com
Disclaimers
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Why was Nanobiotix (NASDAQ:NBTX) trading halted on Euronext Paris on May 21, 2026?
Trading in Nanobiotix ordinary shares on Euronext Paris was halted at the company’s request. According to Nanobiotix, the halt supports confirming investor allocations and announcing pricing for its previously announced Global Offering in the United States and Europe.
When will Nanobiotix (NBTX) trading resume on Euronext Paris after the May 21, 2026 halt?
Nanobiotix expects trading in its ordinary shares on Euronext Paris to resume May 21, 2026. According to Nanobiotix, the planned restart time is approximately 3:30 p.m. Paris time, corresponding to about 9:30 a.m. in New York.
What is the Global Offering mentioned in Nanobiotix (NBTX) May 21, 2026 trading halt announcement?
The Global Offering combines a U.S. public ADS offering with an international offering of ordinary shares and pre-funded warrants. According to Nanobiotix, the international tranche targets qualified investors in Europe and certain other countries, excluding the United States and Canada.
How are Nanobiotix (NBTX) ADSs and ordinary shares involved in the May 2026 Global Offering?
The Global Offering includes American Depositary Shares in the United States and ordinary shares plus pre-funded warrants internationally. According to Nanobiotix, each ADS represents one ordinary share with a nominal value of €0.03 per share.
Is the Nanobiotix (NBTX) trading halt on Euronext Paris related to pricing of its Global Offering?
Yes, the trading suspension is directly connected to the Global Offering process. According to Nanobiotix, the halt allows time to confirm investor allocations and to announce the final pricing terms for the combined U.S. and international offerings.
